Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973369 | 0.89 | ALDH1A1 (0.40) | MAPTHSD17B10KMT2ATSHRNPSR1 | |
| SCHEMBL1971695 | 0.89 | MAPT (0.41) | MAPTHSD17B10KMT2ATSHRNPSR1 | |
| SCHEMBL21054378 | 0.82 | CA12 (0.40) | MAPTHSD17B10KMT2ATSHRNPSR1 | |
| SCHEMBL319034 | 0.82 | GSK3B (0.53) | MAPTHSD17B10KMT2ATSHRNPSR1 | |
| SCHEMBL1374020 | 0.81 | TSHR (0.44) | MAPTHSD17B10KMT2ATSHRNPSR1 | |
| SCHEMBL2730725 | 0.81 | MAPT (0.44) | MAPTHSD17B10KMT2ATSHRNPSR1 | |
| SCHEMBL168008 | 0.81 | MAPT (0.40) | MAPTHSD17B10KMT2ATSHRNPSR1 | |
| SCHEMBL20269630 | 0.79 | ABL1 (0.42) | MAPTHSD17B10KMT2ATSHRNPSR1 | |
| SCHEMBL27191784 | 0.79 | GAA (0.55) | MAPTHSD17B10KMT2ATSHRCA12 | |
| SCHEMBL1371646 | 0.79 | KMT2A (0.42) | MAPTHSD17B10KMT2ATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3559005-A1 | THIENOPYRROLE DERIVATIVES FOR USE IN TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Biotheryx Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180298027-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2018-10-18 | — | — | US | disclosed |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2018118947-A1 | THIENOPYRROLE DERIVATIVES FOR USE IN TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-9000006-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8703795-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-1866318-B1 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN INC (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-1866318-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006094292-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | MAPT 3256/4885HSD17B10 3718/4885KMT2A 1140/4885 |
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | MAPT 774/4885HSD17B10 4503/4885KMT2A 3777/4885 |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, CKS2 | MAPT 834/4885HSD17B10 4456/4885KMT2A 3856/4885 |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | HIF1AN, HIF1A, EGLN2 | MAPT 3256/4885HSD17B10 3718/4885KMT2A 1140/4885 |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | MAPT 774/4885HSD17B10 4503/4885KMT2A 3777/4885 |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | MAPT 774/4885HSD17B10 4503/4885KMT2A 3777/4885 |
| US-20180298027-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | MAPT 774/4885HSD17B10 4503/4885KMT2A 3777/4885 |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | MAPT 774/4885HSD17B10 4503/4885KMT2A 3777/4885 |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | MAPT 774/4885HSD17B10 4503/4885KMT2A 3777/4885 |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | MAPT 774/4885HSD17B10 4503/4885KMT2A 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.